Other substances

Azelastine

A phtalazine antihistamine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
0
 Clinical trials

General information

Azelastine is a phthalazine antihistamine, which acts as a histamine H1-receptor antagonist. It has also anti-asthmatic, bronchodilator, and platelet aggregation inhibitor properties (ChEBI).

Azelastine on DrugBank
Azelastine on PubChem
Azelastine on Wikipedia

Marketed as

ASTELIN; ASTEPRO; AZELASTINE HYDROCHLORIDE; OPTIVAR

 

Structure image - Azelastine

CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of SARS-CoV-2 entry inhibitors among already approved drugs
Small molecule In vitro Screening 		Huh-7 cells (pseudovirus-based assay); Vero E6 cells (antiviral activity); SARS-CoV-2 (WIV04) 5.06

Inhibits SARS-CoV-2 spike protein pseudovirus cell entry and significally inhibits viral replication in vitro.

 Oct/28/2020

AI-suggested references

Link Publication date
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.
May/25/2021
Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Mar/31/2020
Identification of antiviral antihistamines for COVID-19 repurposing.
Dec/03/2020
Export (.csv)